Literature DB >> 17956579

Autoantibody epitopes to the smaller isoform of glutamate decarboxylase do not differ in Swedish and Japanese type 1 diabetes patients and may be associated with high-risk human leucocyte antigen class II alleles.

T Maruyama1, S Oak, T R Hall, J P Banga, E Ortqvist, R A Ettinger, J Endl, C S Hampe.   

Abstract

Type 1 diabetes (T1D) is an autoimmune disease with a strong human leucocyte antigen (HLA) class II association. Depending on geographic locations, the disease-associated HLA class II alleles vary. We evaluated the beta cell-specific autoimmunity reflected in autoantibodies directed to the smaller isoform of glutamate decarboxylase (GAD65) in Japanese and Swedish T1D patients. GAD65Ab epitope specificities were assessed using GAD65-specific recombinant Fab. GAD65Ab epitope specificities did not differ between Swedish and Japanese patients. Only recognition of the MICA-4-defined middle epitope was significantly stronger in the Japanese T1D patient group compared to the Swedish T1D patients (P = 0.001). Binding to the b96.11-defined middle epitope was substantial in both groups and showed significant associations with high-risk HLA class II haplotypes. In the Japanese T1D group the association was with haplotype DRB1*0802-DQB1*0302 (P = 0.0008), while in the Swedish T1D patients binding to the b96.11-defined epitope as associated with the presence of high-risk HLA genotypes DR3-DQB1*0201 and/or DR4-DQB1*0302 (P = 0.02). A significant association between reduction in binding in the presence of recombinant Fab (rFab) DPD and high-risk allele DQB1*0201 was found (P = 0.008) in the Swedish T1D patients only. We hypothesize that epitope-specific autoantibodies effect the peptide presentation on HLA class II molecules by modulating antigen uptake and processing. Molecular modelling of the high-risk HLA class II molecules will be necessary to test whether these different molecules present similar peptide-binding specificities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17956579      PMCID: PMC2219379          DOI: 10.1111/j.1365-2249.2007.03527.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase.

Authors:  H L Schwartz; J M Chandonia; S F Kash; J Kanaani; E Tunnell; A Domingo; F E Cohen; J P Banga; A M Madec; W Richter; S Baekkeskov
Journal:  J Mol Biol       Date:  1999-04-16       Impact factor: 5.469

2.  Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes.

Authors:  J Tremble; N G Morgenthaler; A Vlug; A C Powers; M R Christie; W A Scherbaum; J P Banga
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

3.  Associations of GAD65- and IA-2- autoantibodies with genetic risk markers in new-onset IDDM patients and their siblings. The Belgian Diabetes Registry.

Authors:  C L Vandewalle; A Falorni; A Lernmark; P Goubert; H Dorchy; W Coucke; C Semakula; B Van der Auwera; L Kaufman; F C Schuit; D G Pipeleers; F K Gorus
Journal:  Diabetes Care       Date:  1997-10       Impact factor: 19.112

4.  Allele-specific motifs characterize HLA-DQ interactions with a diabetes-associated peptide derived from glutamic acid decarboxylase.

Authors:  W W Kwok; M L Domeier; F C Raymond; P Byers; G T Nepom
Journal:  J Immunol       Date:  1996-03-15       Impact factor: 5.422

5.  HLA class II is associated with the frequency of glutamic acid decarboxylase M(r) 65,000 autoantibodies in Japanese patients with insulin-dependent diabetes mellitus.

Authors:  A Kasuga; A Falorni; T Maruyama; Y Ozawa; C E Grubin; K Matsubara; I Takei; T Saruta; A Scheynius; A Lernmark
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

Review 6.  The genetic basis of autoantibody production.

Authors:  John D Reveille
Journal:  Autoimmun Rev       Date:  2005-12-27       Impact factor: 9.754

7.  High prevalence of GAD65 (and IA-2) antibodies in Japanese IDDM patients by a new immunoprecipitation assay based on recombinant human GAD65.

Authors:  H Akamine; I Komiya; T Shimabukuro; T Asawa; H Tanaka; N Yagi; T Taira; K Nagata; K Arakaki; T Wakugami; N Takasu; M J Powell; J Furmaniak; B R Smith
Journal:  Diabet Med       Date:  1997-09       Impact factor: 4.359

8.  Mapping of an autoreactive epitope within glutamate decarboxylase using a diabetes-associated human monoclonal autoantibody and an epitope cDNA library.

Authors:  W Richter; W Northemann; M Müller; B O Böhm
Journal:  Hybridoma       Date:  1996-04

9.  Autoantibodies against glutamic acid decarboxylase 65 in Japanese patients with insulin-dependent diabetes mellitus (IDDM).

Authors:  M Yano; R Moriuchi; E Kawasaki; M Watanabe; K Saito; H Takino; S Akazawa; T Miyamoto; S Nagataki
Journal:  J Autoimmun       Date:  1995-02       Impact factor: 7.094

10.  Four IgG anti-islet human monoclonal antibodies isolated from a type 1 diabetes patient recognize distinct epitopes of glutamic acid decarboxylase 65 and are somatically mutated.

Authors:  A M Madec; F Rousset; S Ho; F Robert; C Thivolet; J Orgiazzi; S Lebecque
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

View more
  2 in total

1.  DPD epitope-specific glutamic acid decarboxylase (GAD)65 autoantibodies in children with Type 1 diabetes.

Authors:  N Bansal; C S Hampe; L Rodriguez; E O'Brian Smith; J Kushner; A Balasubramanyam; M J Redondo
Journal:  Diabet Med       Date:  2016-02-12       Impact factor: 4.359

2.  GAD65 autoantibody responses in Japanese latent autoimmune diabetes in adult patients.

Authors:  Taro Maruyama; Shilpa Oak; Akira Shimada; Christiane S Hampe
Journal:  Diabetes Care       Date:  2008-05-16       Impact factor: 19.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.